Earlier quoted context omitted.
Now that it's been proven and the manufacturing scaled, there may be a fair bit of profit in it. If tuberculosis, MRSA, and even malaria can be targets, that would be world-changing. I'm not even sure how "cancer" is really a target -- are they talking about individualized treatments for your specific cancer cells?
The process generally relies on discovery of potent neoantigens within the somatic mutations and then building mRNA to express it. So, yes, the idea is individualized treatment for cancer. I’m not sure there is any relevance for organism-scale immunity like TB/MRSA/malaria.
An individualized vaccine for cancer has to be created and administered fast, within the course of a specific patient’s cancer treatment.